Serhan Unlu

[Jame Abraham, MD, FACP @jamecancerdoc]

Congratulations to @SerhanUnlu2 one of the best residents and aspiring oncologist @CleClinicMD @ClevelandClinic @SABCSSanAntonio - real world experience with neuro endocrine tumors of breast!

[Olisaemeka Ogbue, MD @olisaogbue]

Rising PGY2 @SerhanUnlu2 presenting our Cleveland clinic experience with neuroendocrine neoplasms (NEN) of the breast.
Trend towards worse OS in higher grade NEN with conventional treatment strategies.
#SABCS23 @OncoAlert @AACR

[Jame Abraham, MD, FACP @jamecancerdoc]

Please join me in congratulating and welcoming an outstanding group of doctors to ⁦@CleClinicMD⁩ ⁦@ClevelandClinic⁩ Hematology and Medical Oncology Fellowship family!! We are thrilled to see number of our own ⁦@CCF_IMCHIEFS⁩ ⁦@ChrisWeeMD⁩ ⁦

[Serhan Unlu @SerhanUnlu2]

Only made possible with the support of world's best mentor!

[Joseph W Kim @Joseph_W_Kim]

@SerhanUnlu2 did an amazing job reviewing this topic and provides a roadmap on where we are w #parpinhibitor prostate cancer #ProstateCancerAwarenessMonth

[Amanda Nizam, MD @AmandaNizamMD]

📣 Heme Onc Fellows searching for jobs in academia, see👇🏼! Sign up to meet with outstanding early career faculty & get invaluable guidance on the job search! Retweet to share w/other fellows! #ASCO22 @dr_simkins @RyanRaderMD @YuWeiChenMD @MadisonConces @LoganRoofMD @KunalDesaiMD

[Zeynep Zengin @ZeynepZengin]

Honored to share that I will be serving on @ASCO’s Trainee and Early Career Advisory Board.

Like Rumi says, I hope we can be a lamp, or a lifeboat, or a ladder to someone…🎈

[Yale Cancer Center @YaleCancer]

Pat LoRusso, DO, will chair and present during the ‘KRAS Anniversary Session: Novel Mechanisms for Targeting KRAS: The clinical successes & challenges of drugging KRAS’ at 12:30pm today #AACR22 @AACR @YaleMed @OncoAlert https://t.co/80am1psGoP

[Yale Internal Medicine Chiefs @YaleIM_Chiefs]

So proud of @NazliDizman!

[Sumanta K. Pal, MD, FASCO @montypal]

Such important work from @neerajaiims @huntsmancancer & colleagues in @JAMANetworkOpen. Well done team! @PGrivasMDPhD @TDorffOnc @EdwinPosadasMD @jgong15 @DrRanaMcKay

[Roy Herbst @DrRoyHerbst]

Our first medical grand rounds in person (actually hybrid) in two years @YaleIMed @YaleIM_Chiefs Our new cancer center director Dr. Eric Winer @YaleCancer @SmilowCancer is the Paul Beeson professor speaking about advances in the treatment of breast cancer @ASCO @BCRFcure

[Rana McKay, MD, FASCO @DrRanaMcKay]

177Lu-PSMA finally receives FDA approval! Huge breakthrough for patients. Indication in PSMA positive disease post ARTA and taxane. ⁦@morr316⁩ ⁦@ALLIANCE_org⁩ ⁦@DrScottTagawa⁩ ⁦@PCFnews⁩ https://t.co/j98DploF37

[Yale Cancer Center @YaleCancer]

.@Cecchini_OncMD in honor of #ColorectalCancerAwarenessMonth – “We learn what members of our community are doing to advance #colorectalcancer research and ways we can collaborate both within and outside @Yale.” https://t.co/xFjqSnZxAB @YaleMed @YNHH @SmilowCancer @YaleGICancers

[Tom Powles @tompowles1]

Data for PARPi and PD(L)1 therapy in prostate ca strongly suggests biomarkers use(BRCA/PD-L1/TMB). The unselected pembro/orlaparib trial (vs Abi or enza) in CRPC patients pretreated with Abi/enza is -ve. Personalised therapy is important for these agents https://t.co/RicOwuHD0n

[Yale Cancer Center @YaleCancer]

Register to join us for a #NeuroendocrineTumor #CME webinar program Thursday, 3/17 at 6:30pmET with @PamelaKunzMD @MariamAboian and Dr. Sajid Khan. #NETs @YaleMed @YNHH https://t.co/PQtjbGCai4

[David Braun @BraunMDPhD]

Out in @NEJM this week, our perspective on some recent outstanding work defining the phenotype of tumor-infiltrating T cells across cancer types, and our thoughts on next steps.

Tumor-Infiltrating T Cells — A Portrait | NEJM https://t.co/WoAI49kbFT

@YaleCancer @YaleMed

[Serhan Unlu @SerhanUnlu2]

@NazliDizman @NatureMedicine @montypal @LuisMezaco @PauloBergerot @crisbergerot @urotoday @ASCO @DrChoueiri @neerajaiims @PGrivasMDPhD @DrRaviSalgia @TDorffOnc @KidneyCancer @kidneycan Congratulations Nazlı!

[CancerTherapyAdvisor @CancerTherAdvsr]

Results from a new study do not clarify whether androgen receptor-directed therapy can prevent poor outcomes in patients with #prostatecancer and COVID-19. Presented at @ASCO #GU22 with @SerhanUnlu2 @DanielPetrylak @Joseph_W_Kim @YaleCancer @YaleMed. https://t.co/czf3eSMBTB

[Shilpa Gupta @shilpaonc]

@PauloBergerot @montypal @NazliDizman @ZeynepZengin @LauraBukavinaMD @LuisMezaco @SerhanUnlu2 @ChawlaNeal @PGrivasMDPhD @neerajaiims @BradMcG04 @drenriquegrande @DMakrakisMD @ASCO Was awesome seeing you! Thanks for being such an impactful #voice of @asco!

[Paulo G Bergerot @PauloBergerot]

Special thanks @montypal @NazliDizman @ZeynepZengin @LauraBukavinaMD @shilpaonc @LuisMezaco @SerhanUnlu2 @ChawlaNeal @PGrivasMDPhD @neerajaiims @BradMcG04 @drenriquegrande @DMakrakisMD
#GU22 @ASCO
😁hope to seeing you at #ASCO22! 😄

[Yale Cancer Center @YaleCancer]

At #GU22, @SerhanUnlu2 @DanielPetrylak & @Joseph_W_Kim report #COVID19 related outcomes of patients with #prostatecancer and #COVID19 on hormone therapy. @SmilowCancer @YaleMed @YNHH @YaleUrology @ASCO https://t.co/c771mfGG0x